Business Wire

TRANE-TECHNOLOGIES

Share
Trane Technologies Launches Innovation for Heating and Cooling With a Single Unit, While Reducing Buildings’ Carbon Footprint

Global climate innovator Trane Technologies (NYSE: TT) announced today the launch of the Sintesis™ Balance CMAF, a fully electric single unit to heat and cool buildings. The air-cooled multi-pipe solution is the latest model in the Sintesis portfolio of high-performance indoor climate systems by Trane®, the company’s HVAC brand. It is initially available for customers in Europe, Middle East, and Africa.

Sintesis Balance is a fully electric unit that delivers hot and chilled water for heating and cooling. It is ideal for buildings with dynamic temperature requirements, such as schools, hotels, hospitals, retail centers, office buildings and theaters.

“The Sintesis Balance eliminates the need for separate boiler and chiller systems, and provides flexibility to meet comfort needs across climates, seasons, use and occupancy, as well as better use of floor space,” said José La Loggia, president of Trane Technologies’ Commercial HVAC in EMEA. “It also provides highly reliable operation, temperature control and indoor air quality. Most systems in Europe use gas or oil boilers, whereas this solution is fully electric. Since buildings contribute to about 15 percent of global carbon emissions, and heating and cooling represents about 35 percent of that, Sintesis Balance is also a major step on the path to electrification and decarbonization of buildings.”

The innovation contributes to Trane Technologies’ Gigaton Challenge, a goal to reduce customers’ greenhouse gas emissions by a billion metric tons by 2030. The unit recovers and repurposes energy without generating its own carbon emissions, significantly reducing fossil fuel use over typical systems that include both a boiler and a chiller. When drawing from a grid that generates electricity from renewable sources, Sintesis Balance has potential to be a zero-emissions solution.

Sintesis Balance Sustainability by the Numbers

Trane Sintesis Balance has an average Total Efficiency Ratio of 8.2; it generates 8 kW of simultaneous cooling and heating from only 1 kW of electric power. It also delivers a Coefficient of Performance (COP) of 3.35, the highest COP among air-sourced multi-pipe unit options. (COP is a measure of how much heat the system produces per unit of energy input).

The technology’s expanded operating map allows for temperature control even in very hot or cold climates. The heating capabilities of the unit make it a good choice for building applications in regions where ambient air temperatures go down to minus 18 degrees Celsius. The unit also can heat water up to 68 degrees Celsius.

Technical features of the Trane Sintesis Balance CMAF

  • Trane Adaptive Refrigerant System™ automatically optimizes refrigerant charge in each operating mode and temperature condition, delivering additional performance and efficiency gains.
  • Fully electric driven CMAF multi-pipe unit doesn’t generate direct greenhouse gas emissions beyond emissions from the electricity grid. It offers up to 350 percent higher efficiency compared to most gas boilers when delivering hot water for comfort heating systems.
  • Configurability with three acoustic packages and efficiency levels to meet different building application requirements.
  • New generation of Trane controls technology – Tracer Symbio™ 800 controller features advanced algorithms ensuring smooth, reliable operation with low cost of ownership. In addition, it also offers six arbitration choices to optimize performances for the application.
  • Tracer Symbio 800 with TD7 AdaptiView™ touchscreen provides facility managers with user-friendly control of the unit. The controller allows them to remotely manage and respond to a variety of conditions and maintain efficient operation with various pre-programmed operating modes.

For more details of on the complete Trane portfolio of solutions for EMEA, please visit www.Trane.eu .

About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. Visit tranetechnologies.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye